1-(3-氟苯基)-4-甲基哌嗪 | 218940-66-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-(3-氟苯基)-4-甲基哌嗪
• 英文名称: N-(3-fluorophenyl)-4-methylpiperazine
• 英文别名: 1-(3-Fluorophenyl)-4-methylpiperazine
• CAS: 218940-66-0
• 化学式: C₁₁H₁₅FN₂
• mdl: MFCD20441884
• 分子量: 194.252
• InChiKey: BITRTHRIXOPUIB-UHFFFAOYSA-N

物化性质

• 沸点：
  281.4±35.0 °C(Predicted)
• 密度：
  1.097±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  1-(3-氟苯基)-4-甲基哌嗪 、 碘甲烷 以 乙醚 为溶剂， 生成 4-(3-Fluorophenyl)-1,1-dimethylpiperazin-1-ium;iodide
  参考文献：
  名称：

  Structure−Affinity Relationships of a Unique Nicotinic Ligand:  N-Dimethyl-N⁴-phenylpiperazinium Iodide (DMPP)

  摘要：

  DMPP is a well-known nicotinic agonist that does not fit any proposed pharmacophore for nicotinic binding and represents a unique ligand among the hundreds of nicotinic agonists studied in the past decades. A systematic modulation of the chemical structure of DMPP, aimed to establish its structure-affinity relationships, is reported. The research has allowed to identify molecules such as I Ic, 13c, 14c, and 28c, with affinities for alpha (4)beta (2) receptors in the low nanomolar range, some 2 orders of magnitude lower than the lead compound. The agonistic properties of the most interesting compounds have been assessed by measuring their analgesic activity on mice (hot-plate test). Another result of the research was the identification of DMPP analogues, such as 3a (K-i = 90 nM) and 14b (K-i = 180 nM), that maintain affinity for the central nicotinic receptor when the ammonium function is changed into an aminic one and are therefore possible leads for drug development in neurodegenerative diseases.

  DOI：

  10.1021/jm010901y
• 作为产物：
  描述：

  聚合甲醛 、 1-(3-氟苯基)哌嗪 在 甲酸 作用下， 以20%的产率得到1-(3-氟苯基)-4-甲基哌嗪
  参考文献：
  名称：

  Structure−Affinity Relationships of a Unique Nicotinic Ligand:  N-Dimethyl-N⁴-phenylpiperazinium Iodide (DMPP)

  摘要：

  DMPP is a well-known nicotinic agonist that does not fit any proposed pharmacophore for nicotinic binding and represents a unique ligand among the hundreds of nicotinic agonists studied in the past decades. A systematic modulation of the chemical structure of DMPP, aimed to establish its structure-affinity relationships, is reported. The research has allowed to identify molecules such as I Ic, 13c, 14c, and 28c, with affinities for alpha (4)beta (2) receptors in the low nanomolar range, some 2 orders of magnitude lower than the lead compound. The agonistic properties of the most interesting compounds have been assessed by measuring their analgesic activity on mice (hot-plate test). Another result of the research was the identification of DMPP analogues, such as 3a (K-i = 90 nM) and 14b (K-i = 180 nM), that maintain affinity for the central nicotinic receptor when the ammonium function is changed into an aminic one and are therefore possible leads for drug development in neurodegenerative diseases.

  DOI：

  10.1021/jm010901y

文献信息

• [EN] TRIAZACYCLODODECANSULFONAMIDE ("TCD")-BASED PROTEIN SECRETION INHIBITORS<br/>[FR] INHIBITEURS DE SÉCRÉTION DE PROTÉINE À BASE DE TRIAZACYCLODODÉCANSULFONAMIDE ("TCD")
  申请人：KEZAR LIFE SCIENCES

  公开号：WO2019178510A1

  公开（公告）日：2019-09-19

  Provided herein are triazacyclododecansulfonamide ("TCD")-based protein secretion inhibitors, such as inhibitors of Sec61, methods for their preparation, related pharmaceutical compositions, and methods for using the same. For example, provided herein are compounds of Formula (I) and pharmaceutically acceptable salts and compositions including the same. The compounds disclosed herein may be used, for example, in the treatment of diseases including inflammation and/or cancer.

  本文提供了基于三氮杂环十二烷磺酰胺（"TCD"）的蛋白质分泌抑制剂，例如Sec61的抑制剂，其制备方法，相关的药物组合物，以及使用它们的方法。例如，本文提供了符合Formula（I）的化合物及其药用盐和包括它们的组合物。本文披露的化合物可以用于治疗炎症和/或癌症等疾病。
• [EN] SPIROALKENE CARBOXAMIDE DERIVATIVES AND THEIR USE AS CHEMOKINE RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS DE SPIROALCÈNECARBOXAMIDE ET LEUR UTILISATION COMME MODULATEURS DE RÉCEPTEURS DE CHEMOKINES
  申请人：ARES TRADING SA

  公开号：WO2012130915A1

  公开（公告）日：2012-10-04

  The present invention is directed to compounds of Formula (I) below, which are antagonists to the chemoattractant cytokine receptor 2 (CCR2), and/or 5 (CCR5), pharmaceutical compositions, and methods for use thereof.

  本发明涉及以下式（I）的化合物，这些化合物是趋化因子细胞因子受体2（CCR2）和/或5（CCR5）的拮抗剂，以及其药物组合物和使用方法。
• OXAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF
  申请人：BARTH Francis

  公开号：US20070043060A1

  公开（公告）日：2007-02-22

  This invention relates to compounds of formula (I): Wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as described herein. The invention further relates to a method for prevention and therapeutic use thereof.

  本发明涉及式(I)化合物：其中R1、R2、R3、R4、R5、R6、R7和R8如本文所述。本发明还涉及其预防和治疗用途的方法。
• SUBSTITUTED THIOPHENE- AND FURAN-FUSED AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS
  申请人：DART NEUROSCIENCE (CAYMAN) LTD.

  公开号：US20160031901A1

  公开（公告）日：2016-02-04

  Described herein are compounds and chemical entities of Formula (I), methods of their synthesis, compositions comprising them, and their use in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.

  本文描述了公式（I）的化合物和化学实体，它们的合成方法，包含它们的组合物，并且它们在治疗许多疾病和疾病障碍方面的用途，包括与中枢神经系统疾病和疾病障碍相关的认知缺陷。
• THERAPEUTIC AGENT FOR TAUOPATHIES
  申请人：Sumitomo Pharma Co., Ltd.

  公开号：EP4104861A1

  公开（公告）日：2022-12-21

  The present invention is to provide a medicament for treating and/or preventing tauopathy by activating the voltage-gated sodium channel (Nav). The present invention relates to a medicament for treating and/or preventing tauopathy, comprising a Nav activator as an active ingredient.

  本发明提供了一种通过激活电压门控钠通道（Nav）治疗和/或预防tau病的药物。本发明涉及一种治疗和/或预防tau病的药物，其包括Nav激活剂作为活性成分。